Does Sonoma Pharmaceuticals Deserve a Place in Your Portfolio?

This post was originally published on this site

Moreover, its shares are highly volatile, and the company also reported disappointing financials in the fiscal first quarter. It reported losses in the quarter, and its top line also decreased. In addition, its debt could widen in the upcoming months. So, SNOA’s near-term prospects look bleak.

Here’s what could influence SNOA’s performance in the upcoming months:

Continue reading on StockNews